Popular Review,and

The BRAF gene, a crucial component of the RAS/MAPK signaling pathway, plays a pivotal role in cellular growth and proliferation. This gene encodes the B-Raf protein, a serine/threonine kinase that is involved in sending signals inside cells, ultimately responsible for transmitting signals from outside the cell to its nucleus. Understanding the BRAF gene sequence and its resulting peptide products is fundamental to comprehending its function and the implications of its mutations in various diseases, particularly cancer.

The BRAF gene itself is a 2949 base pair sequence of 18 exons. This intricate DNA sequence serves as the blueprint for synthesizing the B-Raf protein. The BRAF gene full name is B-Raf proto-oncogene, serine/threonine kinase. Variations within this DNA sequence can lead to the production of different protein isoforms, known as splice variants. For instance, the BRAF gene has been noted to have numerous transcripts, including transcript variant 5 (from RefSeq NM_001374258.1). Studies have also explored the DNA and amino acid sequences of human BRAF and compared them across species, highlighting conserved regions.

The protein translated from the BRAF gene is known as the B-Raf protein. This protein is a key player in signal transduction, phosphorylating downstream targets like MAP2K1, thereby regulating the MAP kinase/ERK cascade. The BRAF protein sequence and its functional domains are critical for its kinase activity. Research has focused on identifying specific Suggested Antigen Peptide Sequences for BRAF Gene for various research and diagnostic purposes.

Mutations in the BRAF gene are frequently observed in human cancers. The most common oncogenic mutation is the V600E substitution within the kinase domain, often referred to as BRAFV600E gene. This mutation leads to constitutive activation of the B-Raf protein, driving uncontrolled cell growth. Understanding the precise BRAF gene sequence underlying these mutations is essential for developing targeted therapies. The BRAF gene location is on chromosome 7q34.

In the realm of therapeutic development, researchers are actively exploring BRAF inhibitors. These can include small molecules that target the active kinase or novel approaches like peptide inhibitors. For example, braftide, a synthetic peptide inhibitor, has been developed. Braftide is a synthetic peptide inhibitor that works via a dual mechanism of action to inhibit BRAF. These peptides are designed based on the structure and function of the B-Raf protein, sometimes derived from its dimer interface. There is also ongoing research into macrocyclic peptide BRAF-WT inhibitors which aim to inhibit paradoxical activation of mutant RAS/BRAF-wt driven pathways.

It's important to note that not all BRAF mutations are equally prevalent or well-understood. For instance, Class II and III BRAF mutations are uncommon events, with limited data on their clinical and biological characteristics. The study of these less common mutations, alongside the more prevalent ones, contributes to a comprehensive understanding of BRAF's role in disease. The BRAF protein's complex regulatory mechanisms and its involvement in various signaling pathways make it a significant area of research in both fundamental biology and clinical oncology. The UniProt database provides comprehensive and freely accessible information on protein sequence and functional information, including details for B-Raf proto-oncogene, serine/threonine kinase.